COVID-19

[Sorrento Therapeutics, Inc.] Sorrento Therapeutics, Inc. announced the completion of enrollment in its Phase Ib study of human allogeneic adipose-derived mesenchymal stem cells infusions to treat COVID-19 induced acute respiratory failure or acute respiratory distress syndrome.

[Nature Reviews Rheumatology] Immune-related manifestations are increasingly recognized conditions in patients with COVID-19, with around 3,000 cases reported worldwide comprising more than 70 different systemic and organ-specific disorders. Although the inflammation caused by SARS-CoV-2 infection is predominantly centred on the respiratory system, some patients can develop an abnormal inflammatory reaction involving extrapulmonary tissues.

[Journal of Translational Medicine] Investigators present a therapeutic platform of MSC-derived exosomes equipped with exogenous iRNAs, that can be employed as a novel therapeutic modality in COVID-19 management.

[ProtoKinetix, Inc. (Business Wire)] ProtoKinetix announced Phase I clinical trials of AAGP® treated islet cells have resumed at the University of Alberta, Edmonton.

[Mucosal Immunology] The authors review how maternal NK cells balance their double duty both in the local microenvironment of the uterus and systemically, during toxoplasmosis, influenza, cytomegalovirus, malaria and other infections that threat pregnancy.

[iScience] Scientists demonstrated that SARS-CoV-2 infection induces a type I IFN response in vitro and in moderate cases of COVID-19.